<DOC>
	<DOC>NCT00002249</DOC>
	<brief_summary>To determine the safety and pharmacokinetics of L-ofloxacin (RWJ 25213) in patients with HIV infection.</brief_summary>
	<brief_title>A Double-Blind Study to Evaluate the Safety and Pharmacokinetics of L-Ofloxacin (RWJ 25213) in Subjects With HIV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<criteria>Inclusion Criteria Patients must have the following: HIV infection. Exclusion Criteria Coexisting Condition: Patients with the following symptoms or conditions are excluded: Active opportunistic infection or neoplasm. High likelihood of death during study. Significant ophthalmologic, renal, hepatic, cardiovascular, hematologic, neurologic, psychiatric,respiratory, or metabolic disease. Donation of &gt; 1 unit blood or acute loss of blood within one month of study entry. Patients with the following prior conditions are excluded: History of opportunistic infection. Previous allergic reaction to ciprofloxacin, norfloxacin, or any other quinolone. Prior Medication: Excluded: Use of any investigational agent within 7 days of entry into study. Use of any medication within 3 days prior to entry (7 days for AZT). Alcohol or drug abuse.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 1991</verification_date>
	<keyword>Anti-Infective Agents, Quinolone</keyword>
	<keyword>Ofloxacin</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>